CAR-T Therapy for Autoimmune Disease in the United Kingdom: What's Actually Happening

Over the past two years, the United Kingdom has quietly become one of the more active countries in the world for testing CAR-T cell therapy — a treatment originally built to fight blood cancers — against severe, treatment-resistant autoimmune disease, chiefly lupus. University College London Hospitals (UCLH), Cambridge University Hospitals, Manchester University NHS Foundation Trust, and King's College London have all taken on distinct pieces of this effort, working alongside the UK biotech Autolus Therapeutics and the National Institute for Health and Research (NIHR). The early results, presented at the American Society of Hematology's 2025 annual meeting, are genuinely encouraging for a small number of patients who had run out of other options. But this remains investigational, early-phase research involving only a handful of people — not an approved treatment, and not something available outside a clinical trial.

The Current Landscape

The centerpiece of UK activity is a Phase 1 study known as CARLYSLE, led by UCL and UCLH researchers in partnership with Autolus, the company that developed the CD19-directed CAR-T product obecabtagene autoleucel (obe-cel, also known as AUTO1). CARLYSLE is testing obe-cel in adults with severe, refractory systemic lupus erythematosus (SLE) who have exhausted standard immunosuppressive options. The trial opened across multiple UK sites, with Manchester's NIHR Clinical Research Facility at Manchester Royal Infirmary recruiting the first patient nationally in November 2024, UCLH treating patients at its London site, and Cambridge University Hospitals (Addenbrooke's) later becoming the first site worldwide to open a related Phase 2 program. By June 2026, UCL researchers were able to report what UCL's own announcement described as "early promise" for the approach — language that reflects genuine optimism among the clinicians involved, tempered by the fact that this is still a first-in-disease trial.

What's Actually Being Tested

Mechanically, obe-cel works the way CAR-T already works in leukemia and lymphoma: a patient's own T cells are collected, genetically engineered to recognize and destroy CD19-expressing B cells — the cells responsible for producing the autoantibodies that drive lupus — and infused back as a one-time treatment. The hope is that a short, intense "reset" of the B-cell compartment could induce a durable remission without the lifelong daily medication lupus patients currently require. Data presented by Autolus at ASH in December 2025 showed nine adults had been dosed in CARLYSLE across two dose levels (50 million and 100 million cells). In the lower-dose cohort, three of six patients (50%) achieved a complete renal response and five of six (83%) met the stringent DORIS remission criterion, with a median follow-up of 12 months and no new disease activity observed. The higher-dose cohort's three patients showed early improvement consistent with those results, though that data is still maturing. All patients showed deep B-cell depletion after infusion.

Separately, King's College London researchers received a roughly $300,000 preclinical grant from the US-based Lupus Research Alliance in March 2025 to develop pCAR19, a next-generation CD19 CAR-T construct designed at King's, aiming for faster, cheaper manufacturing using a point-of-care "Cocoon" bioreactor system that could produce cells in as few as three days. This work remains at the laboratory stage, testing cells from people with active lupus rather than treating patients directly, and is explicitly framed as groundwork for a possible future early-phase trial — not a current patient-facing study.

What the Evidence Shows

The safety picture reported so far is better than typical CAR-T experience in cancer: no dose-limiting toxicities and no cases of ICANS (the neurological toxicity sometimes seen with CAR-T) occurred at the lower dose, and no high-grade cytokine release syndrome (CRS) was reported at either dose — only mild, Grade 1 CRS in a minority of patients. One patient in the higher-dose group experienced transient Grade 3 liver toxicity that resolved. This is a notably gentler toxicity profile than CAR-T therapies typically produce in blood cancer, which is one reason researchers are cautiously hopeful the approach could translate to a chronically ill, non-cancer population. Still, this is a nine-patient, open-label, uncontrolled early trial. There is no randomized comparison to standard care, follow-up is measured in months rather than years, and researchers themselves — including Autolus's own chief development officer — have stressed that durability and long-term safety remain open questions.

Beyond Lupus, and Toward Larger Trials

Autolus has since launched LUMINA, a Phase 2 trial specifically in lupus nephritis (lupus affecting the kidneys) described by the company as having "registrational intent," meaning it is designed with an eye toward eventual regulatory approval rather than purely exploratory research. The UK autoimmune CAR-T effort to date has concentrated almost entirely on lupus; myositis and systemic sclerosis CAR-T programs reported internationally have largely originated outside the UK, and no major UK trial in those specific conditions had been identified in this research.

Regulatory Status

No CAR-T therapy is approved in the UK — or anywhere — for lupus or any other autoimmune disease. All of the UK activity described here takes place under clinical trial authorization, with patients recruited into controlled research protocols rather than receiving a licensed product. The UK's medicines regulator, the MHRA, does operate a fast-track mechanism for promising advanced therapies called the Innovative Licensing and Access Pathway (ILAP), whose first stage — the "Innovation Passport" — Autolus's obe-cel already holds, though that designation was granted in 2021 for the drug's leukemia indication, not for lupus. Any future UK approval for an autoimmune use would require its own, separate regulatory review once trial data mature.

What to Watch For

The next milestones worth tracking are the maturing 100-million-cell cohort data from CARLYSLE, enrollment progress in the LUMINA Phase 2 trial, and whether King's College London's preclinical pCAR19 work advances into an actual early-phase trial. Patient advocacy groups, including LupusUK, have been candid that even if the therapy proves effective, broad patient access remains years away.

Bottom Line

The UK is running some of the most closely watched early-stage CAR-T trials for lupus anywhere in the world, and the preliminary safety and remission signals from UCLH, Cambridge, and Manchester's collaboration with Autolus are a legitimately hopeful development for patients who have run out of treatment options. But "early promise" in a nine-patient Phase 1 trial is exactly that — early. This is not an approved therapy, it is not widely available, and it carries real, if so-far manageable, risks including liver toxicity and cytokine release syndrome. Anyone encountering claims of a "CAR-T cure" for lupus or other autoimmune disease outside a registered UK clinical trial should treat them with serious skepticism.